Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Clasp Doses First Patient in Trial Of Novel Cancer-Specific T-Cell Engager
Details : CLSP-1025 exclusively targets cancer cells expressing the p53R175H mutation, a mutation associated with a wide range of solid tumors.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 28, 2025
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Details : CLSP-1025 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
January 16, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Catalio Capital Management
Deal Size : $150.0 million
Deal Type : Financing
Clasp Launches with $150 Million to Pioneer Precision Immuno-Oncology
Details : The net proceeds will pioneer precision immuno-oncology using next-generation T cell engagers, bispecific antibody-like molecules designed to bind both a T cell and a tumor-specific mutant peptide.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
March 20, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Catalio Capital Management
Deal Size : $150.0 million
Deal Type : Financing
Reset All
